Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis

Gene Therapy

Volumn 10, Issue 18, 2003, Pages 1592-1599

  Ha, S J ^a   Jeon, B Y ^b   Kim, S C ^b   Kim, D J ^a   Song, M K ^a   Sung, Y C ^a   Cho, Sang Nae ^b,c  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

Ag85A; Chemotherapy; DNA vaccine; IL 12N220L; Mycobacterium tuberculosis

Indexed keywords

ANTIGEN; ANTIGEN 85A; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; ISONIAZID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; FEMALE; GENE THERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TUBERCULOSIS; VACCINES, DNA;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0041375540     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302057     Document Type: Article

References (46)

1. Kochi A, Nunn P, Dye C, Tayler E. Global burden of disease. Lancet 1997; 350: 142 (letter).
2. Toossi Z, Ellner JJ. Pathogenesis of tuberculosis. In: Friedman LN (ed). Tuberculosis: Current Concepts and Treatment. CRC Press: New York, 2001, pp 19-47.
3. Rieder HL. Interventions for Tuberculosis Control and Elimination. International Union Against Tuberculosis and Lung Disease: Paris, 2002.
4. Broekmans JE. Control strategies and programme management. In: Porter JDH, McAdam KPWJ (eds). Tuberculosis: Back to the Future. John Wiley and Sons: New York, 1994, pp 171-192.
5. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. J Am Med Assoc 1998; 279: 943-948.
6. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
7. Young DB, Robertson DB. Approaches to combat tuberculosis. Curr Opin Biotechnol 1998; 9: 650-652.
8. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001; 22: 160-168.
9. Boom WH, Wallis RS, Chervenak KA. Human Mycobacterium tuberculosis-reactive CD4+ T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. Infect Immun 1991; 59: 2737-2743.
10. Kaufmann SH. Immunity to intracellular bacteria. Annu Rev Immunol 1993; 11: 129-163.
11. Tan JS et al. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997; 159: 290-297.
12. Bonato VLD et al. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998; 66: 169-175.
13. Altare F et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432-1435.
14. Stenger S et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 121-125.
15. Denis O et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998; 66: 1527-1533.
16. Huygen K et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
17. Lozes E et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997; 15: 830-833.
18. Kamath AT et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67: 1702-1707.
19. Tascon RE et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888-892.
20. Lowrie DB et al. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997; 15: 834-838.
21. Tanghe A et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999; 162: 1113-1119.
22. Turner J et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68: 1706-1709.
23. Repique CJ, Li A, Collins FM, Morris SL. DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 2002; 70: 3318-3323.
24. Lowrie DB et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271.
25. Lowrie DB, Silva CL. Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 2000; 18: 1712-1716.
26. Ha SJ et al. Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat Biotechnol 2002; 20: 381-386.
27. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123: 445-468.
28. Cooper AM et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178: 2243-2247.
29. Flynn JL et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
30. Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491-494.
31. Dieli F et al. Change of Th0 to Th1 cell-cytokine profile following tuberculosis chemotherapy. Scand J Immunol 2000; 52: 96-102.
32. Wilkinson RJ et al. Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentalization, and effect of chemotherapy. J Infect Dis 1998; 178: 760-768.
33. Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vaccine 2000; 19: 618-622.
34. Zhang M et al. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995; 63: 3231-3234.
35. Song CH et al. Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. Infect Immun 2000; 68: 4477-4484.
36. Huygen K et al. Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand J Immunol 1988; 27: 187-194.
37. Torres M et al. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun 1998; 66: 176-180.
38. Skeiky YA et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000; 165: 7140-7149.
39. Pathan AA et al. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001; 167: 5217-5225.
40. Cooper AM et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84: 423-432.
41. Silva RA, Florido M, Appelberg R. Interleukin-12 primes CD4+ T cells for interferon-gamma production and protective immunity during Mycobacterium avium infection. Immunology 2001; 103: 368-374.
42. Cooper AM et al. Mice lacking bioactive IL-12 can generate protective antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002; 138: 1322-1327.
43. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186: 39-45.
44. Holland SM, Dorman SE. Interleukin-12 (IL-12) treatment in interferon gamma refractory pulmonary M. abscessus infection: clinical response and immunologic reconstitution. J Invest Med 1998; 46(suppl): 218A.
45. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428-5435.
46. Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998; 72: 8430-8436.